Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine for cognitive deficits in post-COVID-19 condition
NCT05047952Phase 2Completed
- Sponsor
- Brain and Cognition Discovery Foundation
- Start
- Sep 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vortioxetine in post-COVID-19 condition (PCC), sponsored by Brain and Cognition Discovery Foundation. Started Sep 2021; status: completed.
02
Drugs
vortioxetine
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT05047952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047952.